Compare American Water Works Company Inc (AWK) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Water Works Company Inc vs BIO-TECHNE Corp — how do they compare? American Water Works Company Inc trades at $131.69 (market cap $25.69B), while BIO-TECHNE Corp trades at $71.23 (market cap $11.12B). The key difference: American Water Works Company Inc is far larger — about 2.3× BIO-TECHNE Corp's market cap, and American Water Works Company Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| AWK | TECH | |
|---|---|---|
Market Cap | $25.69B | $11.12B |
Sector | Utilities | Health |
52-Week High | $147.00 | $71.38 |
52-Week Low | $121.13 | $43.31 |
Enterprise Value | $41.25B | $11.20B |
Dividend Yield | 2.72% | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Water Works Company Inc
American Water Works is the largest investor-owned U.S. water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's only nonregulated business is water services for military bases, which operates under long-term contracts.
Read more on AWK →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
